Ohad Hammer
Partner @ Pontifax
Tel Aviv, Israel
Ohad Hammer is a Series A investor at Pontifax in Tel Aviv focused on Biotechnology and Health Care. Ohad Hammer - Partner @ Pontifax
- Total investments:
- 20
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Ohad Hammer invests in
Stages Ohad Hammer invests in
Countries Ohad Hammer invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (40%)
- Health Care 5 (25%)
- Pharmaceutical 3 (15%)
- Wellness 2 (10%)
- Therapeutics 2 (10%)
Stage
- Series A 8 (40%)
- Series B 6 (30%)
- Series C 3 (15%)
- Seed 1 (5%)
- Post-IPO Equity 1 (5%)
Country
- France 4 (20%)
- Belgium 2 (10%)
- Israel 1 (5%)
- Denmark 1 (5%)
- Germany 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M / Series C / Apr 14, 2026 | |
Adcytherix
|
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M / Series A / Oct 16, 2025 | |
Step Pharma
|
Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M / Series C / Oct 15, 2025 | |
Kamari Pharma
|
Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology. | $23M / Series A / Jun 03, 2025 | |
|
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $135M / Series B / Nov 25, 2024 | |
|
Adcytherix
|
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $32.2M / Seed / Jun 11, 2024 | |
|
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $17.3M / Series A / May 29, 2024 | |
Climb Bio
|
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $120M / Post-IPO Equity / Apr 11, 2024 | |
AgomAb Therapeutics
|
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $100.8M / Series C / Oct 11, 2023 | |
|
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $34M / Series A / Apr 04, 2023 | |
| See all 20 investments → | |||
Co-Investors
About Pontifax
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Pontifax Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ohad Hammer
Partner
|
|||
Ran Nussbaum
Managing Partner and Co-Founder
|
|||
Tomer Kariv
Co-Founder and Chief Executive Officer
|
|||
|
Momi Karako
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ohad Hammer invest in?
Ohad Hammer invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ohad Hammer?
Public channels for Ohad Hammer include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ohad Hammer last invest?
The most recent investment recorded for Ohad Hammer closed in Apr 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
